Questions: Mineral Homeostasis: Calcium, Phosphorus, and Magnesium Regulation

Question 1

Serum calcium drops suddenly. Which sequence of events correctly describes the immediate hormonal response?

• A. Calcitriol is secreted directly by the parathyroid glands to stimulate intestinal calcium absorption within minutes
• B. PTH is released within seconds to minutes; it simultaneously increases renal calcium reabsorption, activates osteoclasts to release bone calcium, and stimulates renal conversion of vitamin D to calcitriol
• C. FGF23 is released from bone cells, which signals the kidney to retain both calcium and phosphate
• D. Magnesium is mobilized from bone to temporarily substitute for calcium in serum

Answer: (B)

PTH is the fastest-responding calcium regulator — released within seconds of hypocalcemia. It acts on three targets simultaneously: kidneys (reabsorb Ca²⁺, excrete PO₄³⁻), bone (activate osteoclasts to release Ca²⁺ and PO₄³⁻), and kidney again (convert inactive vitamin D to calcitriol, which then increases intestinal Ca²⁺ absorption). Calcitriol is produced by the kidney, not secreted by the parathyroid gland; its intestinal effects take hours. FGF23 regulates phosphate, not calcium. Magnesium is a cofactor for PTH secretion itself, not a surrogate for calcium.

Question 2

A patient with advanced chronic kidney disease develops secondary hyperparathyroidism with persistently elevated PTH. The primary hormonal drivers of this condition are...

• A. Excess dietary phosphate directly stimulating the parathyroid glands to secrete more PTH
• B. Reduced renal calcitriol production and impaired phosphate excretion, both of which depress serum calcium and drive continuous PTH secretion that the damaged kidney cannot adequately respond to
• C. FGF23 deficiency causing uncontrolled phosphate retention and secondary PTH release
• D. Direct destruction of parathyroid tissue by uremic toxins, causing dysregulated PTH secretion

Answer: (B)

In CKD, two parallel failures converge. First, impaired renal 1α-hydroxylase reduces calcitriol production, lowering intestinal calcium absorption. Second, failing kidneys cannot excrete phosphate normally, causing hyperphosphatemia. Both low calcitriol and high phosphate suppress serum calcium, which triggers PTH release. But the damaged kidney responds poorly to PTH's signals (reduced calcium reabsorption, impaired vitamin D activation), so PTH keeps rising — secondary hyperparathyroidism. The result is sustained osteoclast activation, bone loss, and a rising Ca×P product that risks soft-tissue calcification.

Question 3

PTH raises serum calcium primarily through increased intestinal absorption of dietary calcium.

• T. True
• F. False

Answer: False

PTH raises serum calcium through three mechanisms, with intestinal absorption being the slowest and most indirect. PTH's immediate actions are: (1) renal calcium reabsorption (minutes), (2) osteoclast activation releasing calcium from bone (minutes to hours). Only then does PTH stimulate renal calcitriol production, and calcitriol subsequently increases intestinal absorption — a process taking hours. In acute hypocalcemia, bone and kidney effects are the primary rapid rescue mechanisms. Intestinal absorption matters for long-term calcium balance but is too slow to correct an acute drop.

Question 4

Severe magnesium deficiency can cause low serum calcium even when the parathyroid glands are structurally normal and functioning.

• T. True
• F. False

Answer: True

Magnesium is required as a cofactor for PTH secretion from parathyroid cells. In severe hypomagnesemia, PTH secretion is blunted despite hypocalcemia — the parathyroid glands 'want' to respond but cannot without sufficient magnesium. The result is a paradox: hypocalcemia without the expected PTH surge. This is clinically important because administering calcium supplements to such a patient is ineffective; the underlying magnesium deficiency must be corrected first to restore PTH signaling and allow calcium regulation to resume.

Question 5

Explain why the calcium-phosphorus product (Ca × P) is monitored in chronic kidney disease patients, and what happens when it rises above the solubility threshold.

Model answer: The Ca×P product reflects the risk that calcium phosphate will spontaneously precipitate out of solution into soft tissues. When the product exceeds approximately 55 mg²/dL² (using conventional units), the concentration of both ions surpasses the solubility limit of calcium phosphate, and crystals begin depositing in blood vessels, heart valves, kidneys, and joints — a process called vascular or metastatic calcification. In CKD, phosphate accumulates (impaired excretion) and calcitriol falls (impaired production), disrupting the hormonal axis that normally keeps Ca×P in a safe range. Phosphate binders, calcitriol supplements, and dietary phosphate restriction are all aimed at controlling both sides of this product.

The three-way PTH–vitamin D–FGF23 axis normally maintains Ca×P within safe bounds. PTH mobilizes calcium but dumps phosphate in urine; FGF23 drives phosphate excretion and suppresses calcitriol when phosphate is high. When kidneys fail, both phosphate excretion and calcitriol production collapse, and the entire homeostatic loop loses its effector organ. Monitoring Ca×P gives clinicians a single number that integrates the status of both minerals and the risk of the most dangerous complication of mineral dysregulation in CKD.